Cure8 research brief
This paper identifies a herbal formula that improved inflammation and epithelial barrier repair in a mouse colitis model and highlights specific molecular pathways (CAV1/FAK/paxillin and metabolite pathways) that might be relevant to mucosal healing research in UC.
Researchers, translational scientists, and clinicians interested in mucosal healing mechanisms or preclinical drug discovery for ulcerative colitis.
A preclinical mouse study reports that a traditional Chinese herbal formula (Chishizhi Yuyuliang decoction, “CY”) reduced inflammation and improved mucosal healing in DSS-induced ulcerative colitis. The investigators used histology, cytokine measurements, proteomics and metabolomics, and in vitro Caco-2 cell barrier assays to explore mechanisms.
Key experimental findings reported in the abstract: CY lowered disease activity scores and pro-inflammatory cytokines in mice; proteomics pointed to Caveolin-1 (CAV1) and focal adhesion signaling (FAK/paxillin) as targets; metabolomics highlighted tryptophan and butyrate-related pathways; and serum from CY-treated animals improved barrier function and tight-junction protein expression in LPS-treated Caco-2 cells.
The study is preclinical (mouse model and cell culture) and does not provide clinical trial evidence. The authors suggest these mechanistic results could inform future clinical development of CY-derived agents for UC, but the abstract does not report human data, safety, dosing, or efficacy in patients.
Preclinical study in DSS-induced colitis and Caco-2 cell assays; not evidence of safety or efficacy in people. Findings are mechanistic and hypothesis-generating.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study points to specific immune pathways (especially Th17 differentiation) and molecular targets that might explain DSP’s anti-inflammatory effects in ulcerative colitis, which could guide further preclinical and...
The study identifies a previously unrecognized protein (TNFAIP1) that appears to promote inflammation in ulcerative colitis and proposes a compound (Salidroside) that directly binds and inhibits it in lab and mouse...
This preclinical study suggests cigarette smoke alters gut microbes and metabolites in ways that can either protect or worsen colitis depending on the model; it identifies 4-HBA as a metabolite that reduced inflammation...
